Session » RA – Treatment Poster III

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1433

A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 1429

Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study

1:00PM-3:00PM: Abstract Number: 1418

Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry

1:00PM-3:00PM: Abstract Number: 1417

Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice

1:00PM-3:00PM: Abstract Number: 1424

Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial

1:00PM-3:00PM: Abstract Number: 1435

Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study

1:00PM-3:00PM: Abstract Number: 1431

Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1427

Impact of Upadacitinib versus Abatacept on Individual Disease Outcomes in Patients with Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs

1:00PM-3:00PM: Abstract Number: 1422

Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice

1:00PM-3:00PM: Abstract Number: 1423

Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting

1:00PM-3:00PM: Abstract Number: 1439

Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections

1:00PM-3:00PM: Abstract Number: 1428

Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab

1:00PM-3:00PM: Abstract Number: 1420

Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors

1:00PM-3:00PM: Abstract Number: 1432

Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects

1:00PM-3:00PM: Abstract Number: 1421

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of a Proposed Tocilizumab Biosimilar (MSB11456) versus US‑licensed Tocilizumab: Results of a Randomized, Double-blind, Parallel‑group, Single‑intravenous Dose Study in Healthy Adults (APTURA II)

1:00PM-3:00PM: Abstract Number: 1436

Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1434

Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1438

The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry

1:00PM-3:00PM: Abstract Number: 1419

Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study

1:00PM-3:00PM: Abstract Number: 1430

Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1425

Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases

1:00PM-3:00PM: Abstract Number: 1426

Year-two Follow-up Results of an Observational Study Conducted in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Patients Treated with Infliximab Biosimilar CT-P13 in a Real-life Setting

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].